<p>As a financial analyst, I have extracted and analyzed Fu Yu Corporation Limited's consolidated financial performance for both annual and interim periods based on the provided documents. Please note that detailed quarterly financial statements (Q1, Q3) are not provided in the source documents; interim periods are presented on a half-yearly basis. Full financial statement data for FY2022 is also not consistently available across all metrics in the provided documents.</p>

<p>I have calculated margins and growth rates based on the extracted data. For "Cash conversion (EBITDA / (EBITDA/Capex))", the literal mathematical simplification results in "Capex". Interpreting the intent to analyze how much EBITDA covers Capex, I have instead calculated "EBITDA to Capex Ratio (EBITDA / Capex)" and included a footnote explaining the interpretation of the provided (and ambiguous) formula.</p>

<h2>Consolidated Financial Performance Summary</h2>

<table border="1" style="width:100%; border-collapse: collapse;">
    <thead>
        <tr>
            <th colspan="2">Metric (S$'000)</th>
            <th>FY2022 <sup>[1]</sup></th>
            <th>FY2023 <sup>[2]</sup></th>
            <th>FY2024 <sup>[3]</sup></th>
            <th>1H2023 <sup>[4]</sup></th>
            <th>2H2023 <sup>[5]</sup></th>
            <th>1H2024 <sup>[6]</sup></th>
            <th>2H2024 <sup>[7]</sup></th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td rowspan="2"><b>Revenue</b></td>
            <td>Value</td>
            <td>240,100</td>
            <td>190,381</td>
            <td>191,283</td>
            <td>71,188</td>
            <td>119,193</td>
            <td>126,713</td>
            <td>64,570</td>
        </tr>
        <tr>
            <td>Growth Rate (%)</td>
            <td>-</td>
            <td>-20.7%</td>
            <td>0.5%</td>
            <td>-</td>
            <td>67.4% <sup>[8]</sup></td>
            <td>78.0% <sup>[9]</sup></td>
            <td>-49.0% <sup>[10]</sup></td>
        </tr>
        <tr>
            <td rowspan="2"><b>EBITDA <sup>[11]</sup></b></td>
            <td>Value</td>
            <td>N/A <sup>[1]</sup></td>
            <td>1,617</td>
            <td>10,206</td>
            <td>430</td>
            <td>1,187</td>
            <td>4,514</td>
            <td>5,692</td>
        </tr>
        <tr>
            <td>Margin (%)</td>
            <td>N/A</td>
            <td>0.8%</td>
            <td>5.3%</td>
            <td>0.6%</td>
            <td>1.0%</td>
            <td>3.6%</td>
            <td>8.8%</td>
        </tr>
        <tr>
            <td rowspan="2"><b>Operating Income <sup>[12]</sup></b></td>
            <td>Value</td>
            <td>N/A <sup>[1]</sup></td>
            <td>(9,907)</td>
            <td>(2,041)</td>
            <td>(3,772)</td>
            <td>(6,135)</td>
            <td>523</td>
            <td>(2,564)</td>
        </tr>
        <tr>
            <td>Margin (%)</td>
            <td>N/A</td>
            <td>-5.2%</td>
            <td>-1.1%</td>
            <td>-5.3%</td>
            <td>-5.1%</td>
            <td>0.4%</td>
            <td>-4.0%</td>
        </tr>
        <tr>
            <td rowspan="2"><b>Net Income <sup>[13]</sup></b></td>
            <td>Value</td>
            <td>N/A <sup>[1]</sup></td>
            <td>(10,113)</td>
            <td>(3,892)</td>
            <td>(3,854)</td>
            <td>(6,259)</td>
            <td>72</td>
            <td>(3,964)</td>
        </tr>
        <tr>
            <td>Margin (%)</td>
            <td>N/A</td>
            <td>-5.3%</td>
            <td>-2.0%</td>
            <td>-5.4%</td>
            <td>-5.2%</td>
            <td>0.1%</td>
            <td>-6.1%</td>
        </tr>
        <tr>
            <td rowspan="2"><b>Capex <sup>[14]</sup></b></td>
            <td>Value</td>
            <td>N/A <sup>[1]</sup></td>
            <td>3,962</td>
            <td>6,940</td>
            <td>2,121</td>
            <td>1,841</td>
            <td>3,874</td>
            <td>3,066</td>
        </tr>
        <tr>
            <td>% of Revenue</td>
            <td>N/A</td>
            <td>2.1%</td>
            <td>3.6%</td>
            <td>3.0%</td>
            <td>1.5%</td>
            <td>3.1%</td>
            <td>4.8%</td>
        </tr>
        <tr>
            <td rowspan="2"><b>Net Cash from Operating Activities <sup>[15]</sup></b></td>
            <td>Value</td>
            <td>N/A <sup>[1]</sup></td>
            <td>(4,540)</td>
            <td>3,597</td>
            <td>(2,803)</td>
            <td>(1,737)</td>
            <td>3,654</td>
            <td>(57)</td>
        </tr>
        <tr>
            <td>Cash Conversion (OpCF/EBITDA) (%) <sup>[16]</sup></td>
            <td>N/A</td>
            <td>-280.8%</td>
            <td>35.2%</td>
            <td>-651.9%</td>
            <td>-146.3%</td>
            <td>80.9%</td>
            <td>-1.0%</td>
        </tr>
        <tr>
            <td colspan="2"><b>EBITDA to Capex Ratio (x) <sup>[17]</sup></b></td>
            <td>N/A</td>
            <td>0.41x</td>
            <td>1.47x</td>
            <td>0.20x</td>
            <td>0.64x</td>
            <td>1.16x</td>
            <td>1.86x</td>
        </tr>
    </tbody>
</table>

<p><sup>[1]</sup> FY2022 Revenue from AR, pg 28, "Economic Value Generated and Distributed" table. Other detailed financial metrics for FY2022 are not consistently available in the provided consolidated financial statements or supporting documents, hence marked as N/A.</p>
<p><sup>[2]</sup> FY2023 data from FS Q424, B-i, pg 4 (Twelve Months Ended 31 Dec 2023) and D, pg 10.</p>
<p><sup>[3]</sup> FY2024 data from FS Q424, B-i, pg 4 (Twelve Months Ended 31 Dec 2024) and D, pg 10.</p>
<p><sup>[4]</sup> 1H2023 data derived from Pres H124, pg 11 ("Sales reported for the first half year") for Revenue, and by subtracting 2H2023 from FY2023 for other metrics.</p>
<p><sup>[5]</sup> 2H2023 data from FS Q424, B-i, pg 4 (Six Months Ended 31 Dec 2023) and D, pg 10.</p>
<p><sup>[6]</sup> 1H2024 data derived from Pres H124, pg 11 ("Sales reported for the first half year") for Revenue, and by subtracting 2H2024 from FY2024 for other metrics.</p>
<p><sup>[7]</sup> 2H2024 data from FS Q424, B-i, pg 4 (Six Months Ended 31 Dec 2024) and D, pg 10.</p>
<p><sup>[8]</sup> 2H2023 Revenue Growth calculated against 1H2023. Not a year-over-year comparison.</p>
<p><sup>[9]</sup> 1H2024 Revenue Growth calculated against 1H2023. Pres H124, pg 5, states "Group-wide revenue rose 78.0%, propelled by higher sales for both manufacturing and supply chain management segments."</p>
<p><sup>[10]</sup> 2H2024 Revenue Growth calculated against 2H2023. FS Q424, F-8, pg 29, states "For the six months ended 31 December 2024 ("2H24"), the Group's revenue decreased 45.8% to S$64.6 million from S$119.2 million in 2H23."</p>
<p><sup>[11]</sup> EBITDA calculated as: Loss before tax (Total Group) + Depreciation of property, plant and equipment and investment property + Finance costs + Impairment of property, plant and equipment + Impairment of goodwill. This calculation is for the Total Group (continuing and discontinued operations). <i>Note: The company's AR, pg 8, states a lower "EBITDA from Continuing Operations" (FY2024: S$8.5M, FY2023: S$0.6M), which differs from my derived total Group EBITDA. My calculation is based on the comprehensive "Adjustments for" section in the Consolidated Statement of Cash Flows (FS Q424, D, pg 10).</i></p>
<p><sup>[12]</sup> Operating Income (Total Group) calculated as: Sum of "Results from operating activities" for Continuing Operations and Discontinued Operations (FS Q424, B-i, pg 4).</p>
<p><sup>[13]</sup> Net Income (Total Group) refers to "Loss for the period/year attributable to owners of the Company" (FS Q424, B-i, pg 4).</p>
<p><sup>[14]</sup> Capex refers to "Purchase of property, plant and equipment" (FS Q424, D, pg 10).</p>
<p><sup>[15]</sup> Net Cash from Operating Activities (OpCF) from FS Q424, D, pg 10.</p>
<p><sup>[16]</sup> Cash conversion is presented as OpCF / EBITDA to provide a meaningful insight into cash generation efficiency. The prompt's formula "EBITDA / (EBITDA/Capex)" simplifies to Capex, which does not represent a typical cash conversion metric.</p>
<p><sup>[17]</sup> EBITDA to Capex Ratio is provided to show how much EBITDA covers capital expenditures.</p>

<h2>Trend Analysis</h2>
<h3>Revenue Growth & Composition:</h3>
<ul>
    <li><b>FY2022 to FY2023:</b> The Group experienced a significant revenue decline of 20.7% in FY2023, primarily driven by a decrease in the supply chain management services segment.</li>
    <li><b>FY2023 to FY2024:</b> Revenue stabilized with a slight increase of 0.5%, indicating a potential turnaround. This was "mainly due to higher sales from manufacturing segments amid a challenging operating environment" <sup>[FS Q424, F-8, pg 29]</sup>.</li>
    <li><b>Half-Year Performance:</b> 1H2024 saw a strong 78.0% growth over 1H2023, largely propelled by the supply chain management segment (S$72.0M in 1H2024 vs S$18.6M in 1H2023) <sup>[Pres H124, pg 5]</sup>. However, 2H2024 revenue sharply decreased by 49.0% compared to 2H2023, primarily due to the cessation of supply chain management services in Q4 2024 <sup>[FS Q424, F-8, pg 29]</sup>. This highlights the volatile nature of the discontinued segment and the shift towards manufacturing.</li>
    <li><b>Manufacturing Segment Resilience:</b> Despite the overall Group's fluctuations, the core manufacturing business showed resilience, with FY2024 revenue increasing 10.5% compared to FY2023 <sup>[AR, pg 5; FS Q424, F-8, pg 29]</sup>. This growth was driven by higher sales in Singapore (+20.9%) and Malaysia (+24.9%), offsetting a decline in China operations (-11.8%) <sup>[FS Q424, F-8, pg 29]</sup>.</li>
</ul>

<h3>Margin Evolution:</h3>
<ul>
    <li><b>EBITDA Margin:</b> The Group's EBITDA margin saw a remarkable improvement, rising from 0.8% in FY2023 to 5.3% in FY2024. This trend is consistent in the half-yearly data, with EBITDA margin increasing from 0.6% in 1H2023 to 8.8% in 2H2024. This indicates enhanced operational efficiency and potentially better pricing or cost control, especially within the continuing manufacturing operations.</li>
    <li><b>Operating & Net Income Margins:</b> The Group successfully narrowed its operating and net losses. Operating margin improved from -5.2% in FY2023 to -1.1% in FY2024, and net margin improved from -5.3% to -2.0% over the same period. The slight net profit in 1H2024 (0.1% margin) was a positive sign, though overshadowed by a 6.1% net loss margin in 2H2024 as the discontinued operations finalized their activities.</li>
    <li><b>Gross Profit Margin:</b> The Gross Profit Margin for the manufacturing segment significantly improved from 11.7% in FY2023 to 13.5% in FY2024 <sup>[AR, pg 7]</sup>, contributing to the overall margin recovery. The Group's composite gross profit margin also increased from 7.0% to 8.9% <sup>[FS Q424, F-8, pg 29]</sup>.</li>
</ul>

<h3>Cash Flow Generation:</h3>
<ul>
    <li><b>Operating Cash Flow:</b> The Group successfully turned around its operating cash flow from a significant outflow of S$(4.5) million in FY2023 to an inflow of S$3.6 million in FY2024 <sup>[FS Q424, D, pg 10]</sup>. This was "attributed mainly to lower loss before tax for FY2024, reduce in inventories, and trade and other receivables offset by reduced in trade and other payables" <sup>[FS Q424, F-8, pg 30]</sup>.</li>
    <li><b>EBITDA to Capex Ratio:</b> This ratio improved significantly from 0.41x in FY2023 to 1.47x in FY2024, indicating that the Group's core earnings are now sufficiently covering its capital expenditures, a positive sign for sustainable growth.</li>
    <li><b>Capex Trends:</b> Capital expenditure increased from 2.1% of revenue in FY2023 to 3.6% in FY2024, reflecting increased investment primarily "for the purchase of factory equipment, plant and machineries" <sup>[FS Q424, F-8, pg 30]</sup>, signaling a commitment to strengthening manufacturing capabilities.</li>
</ul>

<h2>MD&A Highlighting Key Recent Trends</h2>
<h3>Key Achievements:</h3>
<ol>
    <li><b>Strong Turnaround in Core Manufacturing Profitability:</b> The Group's manufacturing segment demonstrated remarkable resilience and strategic effectiveness, with its gross profit increasing by 28.1% to S$15.5 million in FY2024 and operating profit for the segment turning from a loss of S$(7.4) million in FY2023 to a profit of S$0.5 million in FY2024 (based on Profit/(Loss) from Continuing Operations, Before Tax for manufacturing segments) <sup>[AR, pg 5, 8]</sup>. This was driven by "higher order volumes from existing customers, as well as new projects secured in the biomedical and consumer segments" <sup>[AR, pg 5]</sup>.</li>
    <li><b>Significant Improvement in Overall Cash Flow and EBITDA:</b> The Group successfully reversed its net operating cash outflow of S$(4.5) million in FY2023 to a net operating cash inflow of S$3.6 million in FY2024. Concurrently, the total Group EBITDA surged from S$1.6 million in FY2023 to S$10.2 million in FY2024, indicating substantial improvements in underlying operational cash generation and profitability before non-cash and financial charges <sup>[FS Q424, D, pg 10]</sup>.</li>
</ol>

<h3>Key Challenges:</h3>
<ol>
    <li><b>Discontinuation of Supply Chain Segment and Related Investigation:</b> The Group ceased all business activities in its supply chain management services segment (FYSCS) in the last quarter of FY2024, incurring a S$3.3 million one-off non-cash impairment of goodwill <sup>[AR, pg 6]</sup>. This decision was due to the "inability to identify a suitable candidate to effectively run and manage the business" <sup>[FS Q424, E-15, pg 27]</sup>. Furthermore, the segment is subject to an ongoing investigation into its past affairs, which led to a qualified audit opinion for FY2024 and recent arbitration ruling against the company for S$1.67 million post-year end <sup>[AR, Note 32, 33, pg 170-171; Independent Auditor's Report, pg 104]</sup>, creating significant uncertainty and potential further liabilities.</li>
    <li><b>Persistent Headwinds and Geopolitical Uncertainty:</b> Management explicitly states that the "operating landscape is expected to remain challenging" due to "geopolitical uncertainty, more customers seek to source production away from China", "longer shipping lead times, higher costs of raw materials and further disruptions to the supply chain", and potential escalation of US-China trade tensions <sup>[AR, pg 6; FS Q424, F-10, pg 30]</sup>. The slower-than-expected recovery in China also directly impacted the Group's China operations, which saw an 11.8% decline in revenue contribution in FY2024 <sup>[FS Q424, F-8, pg 29]</sup>.</li>
</ol>

<h3>Areas of Disconnect between Management Statements and Actual Performance:</h3>
<ol>
    <li><b>Optimistic FY2025 Outlook Amidst Unresolved Investigation and Qualified Audit:</b> Management states they "remain optimistic that financial performance for FY2025 will improve compared to FY2024, barring unforeseen circumstances" and highlight a 20% year-on-year increase in order book at the end of FY2024 <sup>[FS Q424, F-10, pg 30; AR, pg 6]</sup>. However, the external auditor issued a qualified opinion on the FY2024 financial statements due to the "ongoing investigation into affairs of Fu Yu Supply Chain Solutions Pte Ltd" and inability to "determine the potential financial impact, if any, to the Group and the Company in respect of the Claims" <sup>[Independent Auditor's Report, pg 104]</sup>. The recent arbitration ruling for S$1.67 million against FYSCS after year-end also highlights the tangible financial risk. This significant legal and financial uncertainty surrounding a discontinued but material part of the business appears to be a major "unforeseen circumstance" that could directly contradict the stated optimism for FY2025 performance.</li>
    <li><b>Discrepancy in Stated vs. Derived EBITDA from Continuing Operations:</b> The "Financial Highlights" table in the Annual Report (pg 8) explicitly states "EBITDA from Continuing Operations" as S$8.5 million for FY2024 and S$0.6 million for FY2023. However, when calculating EBITDA from the detailed consolidated income statement components (Results from operating activities + Depreciation + Impairment of PPE, all pertaining to continuing operations from FS Q424, Note 12), the derived figures are S$9.1 million for FY2024 and S$0.9 million for FY2023. This discrepancy, particularly for a key non-GAAP metric that management highlights, suggests different underlying definitions or adjustments. This could lead to a lack of clarity for stakeholders attempting to reconcile reported figures with the detailed financial statements.</li>
</ol>

---
<small>
<b>Source Footnotes:</b>
<ul>
    <li>[1] Fu Yu 24 AR_m.md, pg 28, "Economic Value Generated and Distributed" table.</li>
    <li>[2] Fu Yu FS Q424_m.md, pg 4, "B (i) Condensed interim consolidated income statement", "Twelve Months Ended 31 Dec 2023" column; pg 10, "D Condensed interim consolidated statement of cash flows", "Twelve Months Ended 31 Dec 2023" column.</li>
    <li>[3] Fu Yu FS Q424_m.md, pg 4, "B (i) Condensed interim consolidated income statement", "Twelve Months Ended 31 Dec 2024" column; pg 10, "D Condensed interim consolidated statement of cash flows", "Twelve Months Ended 31 Dec 2024" column.</li>
    <li>[4] Fuyu Pres H124_m.md, pg 11, "Sales reported for the first half year" for Revenue; Other metrics derived by subtracting 2H2023 from FY2023 (e.g., 1H2023 EBITDA = FY2023 EBITDA - 2H2023 EBITDA).</li>
    <li>[5] Fu Yu FS Q424_m.md, pg 4, "B (i) Condensed interim consolidated income statement", "Six Months Ended 31 Dec 2023" column; pg 10, "D Condensed interim consolidated statement of cash flows", "Six Months Ended 31 Dec 2023" column.</li>
    <li>[6] Fuyu Pres H124_m.md, pg 11, "Sales reported for the first half year" for Revenue; Other metrics derived by subtracting 2H2024 from FY2024 (e.g., 1H2024 EBITDA = FY2024 EBITDA - 2H2024 EBITDA).</li>
    <li>[7] Fu Yu FS Q424_m.md, pg 4, "B (i) Condensed interim consolidated income statement", "Six Months Ended 31 Dec 2024" column; pg 10, "D Condensed interim consolidated statement of cash flows", "Six Months Ended 31 Dec 2024" column.</li>
    <li>[8] Calculated as (2H2023 Revenue - 1H2023 Revenue) / 1H2023 Revenue.</li>
    <li>[9] Fuyu Pres H124_m.md, pg 5, "1H2024 Review - Revenue" section, first bullet point.</li>
    <li>[10] Calculated as (2H2024 Revenue - 2H2023 Revenue) / 2H2023 Revenue. Fu Yu FS Q424_m.md, pg 29, "F-8 Review of performance of the Group", "Revenue" section.</li>
    <li>[11] EBITDA (Total Group) calculated as: Loss before tax (Total Group) + Depreciation of property, plant and equipment and investment property + Finance costs + Impairment of property, plant and equipment + Impairment of goodwill from Fu Yu FS Q424_m.md, pg 10, "D Condensed interim consolidated statement of cash flows", "Adjustments for" section.</li>
    <li>[12] Operating Income (Total Group) calculated as: Sum of "Results from operating activities" for Continuing Operations and Discontinued Operations from Fu Yu FS Q424_m.md, pg 4, "B (i) Condensed interim consolidated income statement".</li>
    <li>[13] Net Income (Total Group) refers to "Loss for the period/year attributable to owners of the Company" from Fu Yu FS Q424_m.md, pg 4, "B (i) Condensed interim consolidated income statement".</li>
    <li>[14] Capex refers to "Purchase of property, plant and equipment" from Fu Yu FS Q424_m.md, pg 10, "D Condensed interim consolidated statement of cash flows".</li>
    <li>[15] Net Cash from Operating Activities from Fu Yu FS Q424_m.md, pg 10, "D Condensed interim consolidated statement of cash flows".</li>
    <li>[16] Cash conversion is calculated as Net Cash from Operating Activities / EBITDA to provide a more standard representation of cash generation efficiency from operations. The literal interpretation of the prompt's formula "EBITDA / (EBITDA/Capex)" simplifies to Capex, which is not a cash conversion ratio.</li>
    <li>[17] EBITDA to Capex Ratio is calculated as EBITDA / Capex. This metric evaluates the company's ability to cover its capital expenditures with its core earnings.</li>
</ul>
</small>